IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Patent Application of Atty Dkt. 2661-22 M# C# Group Art Unit: CRAPO et al Examiner: Serial No. 10/051,367 January 22, 2003 Date: October 28, 2002 Filed: **CANCER THERAP** Title: Assistant Commissioner for Patents Washington, DC 20231 Sir: INFORMATION DISCLOSURE STATEMENT This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon. Fees are attached as calculated below: Total effective claims after amendment minus highest number \$ 0.00 previously paid for 20 (at least 20) =\$ 18.00 х Independent claims after amendment minus highest number 0.00 \$ (at least 3) =\$ 84.00 previously paid for X. If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) 0.00 Petition is hereby made to extend the current due date so as to cover the filing date of this \$ 0.00 paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00 Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00 First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) Please enter the previously unentered , filed Submission attached Subtotal \$ 0.00 -\$ 0.00 If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. 

Statement filed herewith \$ 0.00 Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00 Assignment Recording Fee (\$40.00) 0.00 Other: **TOTAL FEE ENCLOSED** 0.00

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

**NIXON & VANDERHYE P.C.** 

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

## TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CRAPO et al

Serial No.

10/051,367

Filed:

January 22, 2002

For:

**CANCER THERAPY** 

**Assistant Commissioner for Patents** 

October 28, 2002

Atty. Ref.:

Examiner:

Group:

2661-22

Washington, DC 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT

冈 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C

2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C

2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00

3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

冈 A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

$\boxtimes$	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]						
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier] and						
		a) The required Statement made in item 8 below; or						
		b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.						
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and						
		The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and						
		b) The required Statement is stated in item 8 below.						
	8.	Statement under 37 CFR 1.97(e)						
		The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or						
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
	9.	Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed						

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

Mary J. Wilson Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORM	ATION DISCLOSURE	ATTY. DOCKET NO.			SERIAL NO.					
OIP	CITATION	2661-22			10/051,367	RE	RECEIVED			
' /011 4	ે જો	APPLICANT				NO				
	<del>(</del> <b>X</b> )		CRAPO et al			NOV 0 1 2002				
OCI (Vsees)	shaps if necessary)	FILING	FILING DATE		GROUP	TECH CENTER 1600/2900				
PER	\$	January 22, 2002			TEOR DENTER 1000/2		000/2000			
8 TRANS	MARS		U.S. PATENT (	OCUMENTS						
*EXAMINER							FILING			
OVPE	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	IF APPRO	PRIATE		
0										
9										
OCT 2 8 2002	,;							<del></del>		
& WHOENVE										
							****			
								<del></del>		
<u> </u>										
<del></del>										
			<del>-</del>							
FOREIGN PATENT DOCUMENTS								471011		
	DOCUMENT	DATE		COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO		
	DOCUMENT				- CLASS	T	, <u>, , , , , , , , , , , , , , , , , , </u>			
	WO 00/43395	7/2000		WIPO				<del></del>		
-				·						
					<u> </u>	<u> </u>	<u> </u>			
	OTHER DOC	UMENTS (	including Auth	or, Title, Date, Perl	tinent pages,	etc.)	hyrin Ca	talytic		
	Mackensen et al, "Neuroprotection from Delayed Postischemic Administration of a Metalloporphyrin Catalytic Antioxidant", The Journal of Neuroscience 21(13):4582-4592 (2001)									
	Spasojevic and Batinic	-Haberle, "	Manganese(III)	complexes with por	phyrins and re	lated comp	ounds as	3		
	catalytic scavengers of	superoxid	e", Inorganica C	Chimica Acta 317:23	0-242 (2001)					
								<del></del>		
*Evan:===				Data Canaidarad		-				
*Examiner				Date Considered	l					

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)